1 / 65

Waldenström´s makroglobulinemi

Waldenström´s makroglobulinemi. Eva Kimby M.D. Ph.D Professor Karolinska Institute Center of Hematology Karolinska University Hospital Stockholm, Sweden Fortbildningsdagarna i hematologi Linköping 2 oktober 2014. Disclosures Eva Kimby.

trevor-lloyd
Télécharger la présentation

Waldenström´s makroglobulinemi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Waldenström´smakroglobulinemi Eva Kimby M.D. Ph.D Professor Karolinska Institute Center of HematologyKarolinska University Hospital Stockholm, Sweden Fortbildningsdagarnaihematologi Linköping 2 oktober 2014

  2. Disclosures Eva Kimby • Advisory board : Celgene, Pharmacyclics, Gilead, Jansen, Teva • Föreläsararvode: Roche, Mundipharma, Jansen • Forskningsstöd: Pfizer, Roche

  3. Professor Jan Waldenström Acta Med Scand 1944

  4. Incipientmyelomatosisor essentialhyperglobulinemiawith fibrinogenopenia • Oronasal bleeding • Lymphadenopathy/enlargedlymphnodes • Anemia and thrombocytopenia • Hyperviscosity • Elevatederythrocyte sedimentation rate (SR) • Lymphoid cells and mast-cells in bone marrow Waldenström J. Acta Med Scand 1944

  5. Sjukdomssymptom Anemi/trombocytopeni Relativ anemi (hög plasmavolum) Lymfadenopati B-symptom Hyperviskositet Kryoglobulinemi Cold agglutinin disease (CAD) • Neuropati • Amyloidos

  6. InternationaI Workshop on WM Athens 2002* Paris 2004 Stockholm 2008 Venice 2010 Newport 2012 London 2014 *Owen RG, et al. Clinicopathologicaldefinition of WM SeminOncol. 2003Athens 2002 Enl WHO-klassifikationen 2008: “WM is a lymphoplasmacytic lymphoma” WM – diagnoskriterier

  7. Benmärgsinfiltration • Smålymfoplasmacytiskalymfocyter • Intertrabekulärväxt • Typiskimmunfenotyp • Biopsi med immunfärgning (IHC) • Aspiration och flödescytometri WM – diagnoskriterier

  8. Positivitetför Light chain restricted IgM CD19, CD22, (dim), CD25, CD27 ochCD52 CD5 positiviteti5-20% av fallen Negativitetför CD10, CD23, CD103 ochCD138 Ensubklon, främstplasmaceller , är CD20-negativ och CD138-positiv WM immunofenotyp Paiva B, et al. Leukemia. 2014 Jan;28(1):166-73. Multiparameter flowcytometry for the identificationof the WM'sclone in IgM-MGUS and WM: new criteria for differential diagnosis and risk stratification.

  9. FISH: 6q deletion (gen: BLIMP-1) 6q21 deletion -10% Konventionellcytogenetics 34% med FISH • May have prognostic significance • more aggressive clinical features

  10. M-spike in serum required for WM IrrespectiveofIgMconcentration Splenomegaly+IgM spike • MYD88mutations status • till hjälp vid differentiering från • Marginal zons lymfom (7-10%) • IgM- myeloma • KLL med plasmacytiskdifferentiering (4%) Differential diagnosis:Spleniskmarginal zons lymfom CD22+ and CD11c+

  11. MYD88 L265P mutation in WM • Whole genome sequencing of lymphoplasmacytic cells from 30 WM-pts(paired normal tissue sequencing in 10 pts) • A recurring sequence variant on chr 3p22.2 identified with a single nucleotide change in the myeloid differentiation primary response (MYD88) gene • Sanger sequencing confirmed the MYD88 L265P variant in tumor samples from 26 patients Treon SP, Xu L, Yan G et al. NEJM. 2012;367826-33

  12. Metod för MYD88 L265P • Allele-specific PCR iblod: • Circulating WM-cells – • High concordance BM-blood • if CD19+ selected cells are used for allele-specific PCR • patient-friendly, but not specific

  13. Diagnostic criteria (Mayo): *B-symtom, anemia, hyperviscosity, lymphadenopathy/hepatosplenomegaly MYD88 L265P vid IgM MGUS: 10-87% Vid förekomstav mutation större risk för “malignant evolution”

  14. Hunter Z et al, Blood2014 Somatisk”WHIM-syndrome like” mutation av CXCR4 hos 27% avWM patienter C-X-C chemokine receptor typ 4 (CXCR4)

  15. C-X-C chemokine receptor type 4 (CXCR4) The CXCR4 plays a role for cell trafficking of hematopoietic stem cells and also for clonal B-cells • CXCR4 WHIM mutation is related to high tumor proliferation and extramedullary dissemination and decreasedsurvival in WM patients A prognostic marker? Somatic ”WHIM-syndrome like” CXCR4 C1013G mutation: 20-30 % of WM cases, thus not a diagnostic marker

  16. IgM-MGUS • 15% to 20% of all MGUS • Distinct biological and clinical entity, different from IgG-IgA MGUS for nature and rate of progression: • Evolution into lymphoma (WM) or other related disorders • Higher risk of progression than IgG-IgA MGUS

  17. MGUS: risk factors for evolution

  18. AsymptomatiskWaldenström: • Any size of serum IgM MC • Any degree of BM-LP infiltration at BM biopsy • No symptoms attributable to IgM MC/tumour infiltration • No evolution to overt LPD for at least 12 months from diagnosis

  19. IgM-MGUS och A-WM Risk faktorerförevolution: Hbnivåoch serum MC Uppföljning: Var4-6 månad : Kliniskundersökning Hboch serum Ig M OBS! Tänkpåsekundära problem; neuropati, amyloidos

  20. Utredning vid misstänkt Waldenströms makroglobulinemi

  21. Fler prover: • DAT = direkt antiglobulin test • evprov i termos för köldagglutininer • Kryoglobuliner(vid misstanke om kryoglobulinemi, prov i termos) • Serum viskositet (vid hyperviskositetsymtom eller hög M-komponent >40g/L) • P-FLC = fria lätta kedjor?

  22. Symtom orsakade av M-komponent • Huvudvärk, synrubbningar, blödningar, dyspné, • pgahyperviskositet • Njursvikt, Raynaudfenomen, hudutslag, led- muskel-smärta, • neuropati(pgaKryoglobulinemi typ I och II) • Hemolytiskanemi pga autoantikroppar (I-antigen) • Trombocytopenipga autoantikroppar • Perifer neuropatipga autoantikroppar • mot MAG (myelin-associerad glycoprotein) eller GM1 (ganglioside M1)

  23. När ska behandling inledas? Serum IgM i sig är inte en behandlingsindikation Watchand wait • Anaemia/trombocytopenia • Adenopati/organomegaly • Hyperviskositet • Kryoglobulinaemi • Köldagglutinin • Neuropati • Amyloidos • Transformation

  24. The International prognostic Scoring System for WM (ISSWM) *Adverse covariates:IgM > 70 g/l Age > 65 years β2M > 3mg/l Hb≤ 11.5 g/dl Plts≤ 100 x109/l Morel P, et al.Blood 2009; 113:4163–4170 .

  25. MYD88 L265P as a prognostic marker? WM-cellsharboring the L265P mutation, exhibit constitutive signaling leading to the hyperactivationof NF-κB WM patients without the mutation have worse prognosis? Level of mutation of importance? Quantitative PCR?

  26. Single agents Rituximab (standard or extended schedule) Cladribine/fludarabine Chlorambucil Bortezomib Rituximab-based combinations R + fludarabine/cladribine/pentostatin +cyclophosphamide R + bendamustine R + cyclophosphamide + dexamethasone (DRC) R+ bortezomib Treatment options for WM Treatment recommendations by the 4th International Workshop on WMDimopoulos MA, et al.J Clin Oncol 2009; 27:120–126 Updated at last International Workshop on WM, Newport 2012, in manuscript .

  27. Single-agent therapy Single-agentchlorambucil Single-agentrituximab Low Ig M and cytopenias Plasmapheresis High Ig M - risk of “flare” Old age and slow progression .

  28. Hyperviscosity-related symptoms • Prevention • Reduce IgM before rituximab • Reversing (rapid effect needed) • Headache, breathlesness • Retinopathy • Venous dilatation • Bleeding • Anemia Plasmapheresis for removal of IgM

  29. One randomized trial: WM1 Final results ASH 2011 WM 1- prospective randomized trial Previously untreated WM (339), MZL(37) and LPL Median age: 68 years (40-89) NCRI Lymphoma Clinical Studies Group (UK) Groupe d’Etudes sur la Leucémie Lymphoïde Chronique et la maladie de Waldenström (France) Leblond V et al. J ClinOncol. 2013. 20;31(3):301-7.

  30. Chlorambucil: 8 mg/m2 x10 days/28 days (max 12 cycles) CR+PR: 38.6% • Oral Fludara: 40 mg/m2 orally x5 days/28 days (max 6 cycles) CR+PR: 47.8 % WM 1- prospective randomized trial 07/01-12/09 (n=414)

  31. WM1 progression-free survival 1.0 0.8 0.6 PFS 0.4 0.2 FAMP CHB 0.0 0 20 40 60 80 100 Months Factors influencing PFS Negatively: Clb, albumin<35g/l, ptls<100, age>70y P=0.01

  32. OS 5 years • Chlorambucil: 61.4% [52.9;71.3] • Fludarabine: 70.3% [62.7-78.8] (p=0.04) Survival

  33. The addition of R to front-line therapy with CHOP in Lymphoplasmacyticlymphoma (including WM) • A higher response rate • Longer time to treatment failure Buske C, et al. Leukemia. 2009;23:153-61 CD20 + tumor cells Rituximabofvalue?

  34. Fludarabine/combinations FC and FCR good efficacy • Hematologictoxicities • Grade 3/4 • Neutropenia • Thrombocytopenia • Infections • Transformation • MDS/AML • Purinanalogues • No indication in younger patients if autologous ASCT • is a later alternative

  35. Dexamethasone + rituximab + cyclophosphamide (DRC)1 Cyclophosphamide+prednisone+rituximab (CP-R)2 Bendamustine + rituximab3 Other less toxic combinations 1. Dimopoulos MA, et al. J ClinOncol 2007; 25:3344–3349. 2.Ioakomidis L et al, ClinLymphomaMyeloma. 2009 Mar;9(1):62-6 3. Rummel MJ. Lancet. 2013 Apr 6;381(9873):1203-10.

  36. DRC regimen (n=72) • CR = 7% • PR = 67% • MR = 9% • SD = 8% • PD = 8% Dexamethasone 20 mg IV day 1 Rituximab 375 mg/m2 IV day 1 Cyclophosphamide100 mg/m2 PO BID days1–5 courses repeated every 21 days X6 ORR = 83% Mediantime to 50% IgMreduction: 4.1 mo(range0.7–14) IgM flare: 32% (>25%IgMincrease in 11%of patients) Dimopoulos et al. J Clin Oncol 2007; 25: 3344-9

  37. R-Benda vsR-CHOP: Progression freesurvival Rummel MJ et al.: Blood 2009.114: 168 (abs#405). Lancet. 2013 Apr 6;381(9873):1203-10

  38. Proteosominhibitors= bortezomib carfilzomib • Everolimus decreasein serum IgM level, but increase in BM involvement • Lenalidomideunclear anemia • Carfilzomib, Rituximab and Dexamethasone (CaRD) Highly active neuropathy sparing approach for proteasome-inhibitor based therapy in WM Treon et al, ASH 2013 , abstract 757 Other drugs

  39. BortezomibMulticenter protocol (BDR) Cycle 1 (21-days): bortezomib1.3 mg/m2 on days 1, 4, 8, 11 Cycles 2-5 (35-days): bortezomib1.6 mg/m2 d 1,8,15, 22 Rituximab 375 mg/m2 + Dexa 40 days 1, 8, 15, 22 (8 infusions R) * Progression-free survival: 42 months Peripheral neuropathy in 46% (grade ≥3 in 7%) 8% discontinued bortezomib due to neuropathy ..

  40. WM therapy Single-agentchlorambucil Single-agentrituximab Low Ig M and cytopenias DRC Bortezomib Plasmapheresis High Ig M ....risk of “flare” Old age and slow progression .

  41. DRC versus DRC+ bortezomibsc Proposed European trial:

  42. Bruton’sTyrosine Kinase (BTK) Inhibitor Ibrutinib in patients with relapsed/refractory WM • MYD 88 L265P - trigger NFκB signaling by direct interaction with BTK in WM cells • Ibrutinib420mg/dag under 2 år, eller tills progress ellertoxicitet • MutationsMYD88 L265P hos 49/43 (93%) WHIM-like CXCR4 hos 10/40 (25%) MYD88 Treon et al, ASH 2013, abstract 251

  43. Ibrutinib in relapsed/refractoryWM Response impacted by mutations in CXCR4 but notin MYD88 Major response rate: 77% for patients with wild-type CXCR4 vs 30% in those with WHIM-like CXCR4 mutations (p=0.018) Decreasesin serum IgMM-spike (p=0.012) and improvementsin hemoglobin (p=0.058) greater in patients with wild-type CXCR4 Treon et al ASH 2013, abstract 251

  44. PI3K inhibitors • GS1101/idelalisibinhibits PI3K-delta • a role in lymphocyte activation and mast cell degranulation • Rituximab and alkylating agent-refractory iNHL • 125 enrolled patients: 58% FL, 22% SLL, 12% MZL, 8% LPL/WM Ajay Gopal et al ASH 2013,abstract 85

  45. PI3K-Delta Inhibitor Idelalisibin Patients With Double RefractoryIndolent B-CellLymphoma • ORR: 57% , LPL/WM - ORR :80% • ORR consistent across all subgroups, regardless of number of prior regimens, refractoriness to bendamustine or tumor bulk • Short median FU 9.4 months Gopal G, Salles G, et al 2013, abstract 85

  46. Randomiserad, double-blind, placebo-controllerad Fas 3 Studier • Idelalisibi kombination med • Bendamustin och rituximab(BR) (GileadStudy 125) • eller med • Rituximabalone (GileadStudy 124) • Patienter som ej är aktuella för högdos kemoterapi/SCT Relapse-studier hos oss: Indolent lymphoma

  47. WM Consensus Panel : Recommendations on Response Criteria Weber Det al. Semin Oncol. 2003;30:127-31. Updates Kimby E, et al. ClinLymphomaMyeloma. 2006:6:380-3. Owen RG, et al. Br J Haematol. 2013;160:171-6 Timepointfor response evaluation is crucial

  48. Conversion from PR to CR PR CR Delayed response

  49. Moderna response kriterier Allele specific PCR for MYD88 L265p in CD19+ selected blood cells? NO: Quicker and greater reduction of tumor-cells in blood than in BM, why BM is required

More Related